Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Awards Fast track status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline


Wednesday, 2 Apr 2014 08:33am EDT 

Tetraphase Pharmaceuticals Inc:Says that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline.Tetraphase is investigating the safety and efficacy of eravacycline in its ongoing Phase 3 global clinical program.Says the IGNITE 1 study is evaluating the IV formulation of eravacycline for the treatment of complicated intra-abdominal infections.Says IGNITE 2 is evaluating eravacycline IV-to-oral step-down therapy for the treatment of complicated urinary tract infections. 

Company Quote

10.83
-0.11 -1.01%
2:30pm EDT